CN113906042A - 用于纯化fc区修饰抗体的方法 - Google Patents

用于纯化fc区修饰抗体的方法 Download PDF

Info

Publication number
CN113906042A
CN113906042A CN202080034720.3A CN202080034720A CN113906042A CN 113906042 A CN113906042 A CN 113906042A CN 202080034720 A CN202080034720 A CN 202080034720A CN 113906042 A CN113906042 A CN 113906042A
Authority
CN
China
Prior art keywords
amino acid
protein
residues
antibody
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080034720.3A
Other languages
English (en)
Chinese (zh)
Inventor
若林哲也
清水祐一郎
福永匡宏
真岛英司
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CN113906042A publication Critical patent/CN113906042A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080034720.3A 2019-04-10 2020-04-09 用于纯化fc区修饰抗体的方法 Pending CN113906042A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019074738 2019-04-10
JP2019-074738 2019-04-10
PCT/JP2020/015904 WO2020209318A1 (ja) 2019-04-10 2020-04-09 Ｆｃ領域改変抗体の精製方法

Publications (1)

Publication Number Publication Date
CN113906042A true CN113906042A (zh) 2022-01-07

Family

ID=72752051

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080034720.3A Pending CN113906042A (zh) 2019-04-10 2020-04-09 用于纯化fc区修饰抗体的方法

Country Status (13)

Country Link
US (1) US20220213140A1 (https=)
EP (1) EP3954696A4 (https=)
JP (1) JP7583411B2 (https=)
KR (1) KR20210149779A (https=)
CN (1) CN113906042A (https=)
AU (1) AU2020273072B2 (https=)
BR (1) BR112021020204A2 (https=)
CA (1) CA3136398A1 (https=)
IL (1) IL286982A (https=)
MX (1) MX2021012251A (https=)
SG (1) SG11202110986YA (https=)
TW (2) TW202104244A (https=)
WO (1) WO2020209318A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
CN115850408A (zh) * 2022-09-01 2023-03-28 西安蓝晓科技新材料股份有限公司 一种多肽、融合型多聚体蛋白质及其用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007252368A (ja) * 2006-02-21 2007-10-04 Protenova Co Ltd イムノグロブリン親和性リガンド
EP1992692A1 (en) * 2006-02-21 2008-11-19 Protenova Co., Ltd. Immunoglobulin affinity ligand
EP2690173A1 (en) * 2011-03-25 2014-01-29 Kaneka Corporation Protein for affinity-separation matrix
WO2016098357A1 (en) * 2014-12-19 2016-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
US20160215027A1 (en) * 2013-09-04 2016-07-28 Protenova Co., Ltd. Multimeric immunoglobulin-binding domain
WO2017104783A1 (en) * 2015-12-18 2017-06-22 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9022547D0 (en) 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
CA2131151A1 (en) 1992-03-24 1994-09-30 Kevin S. Johnson Methods for producing members of specific binding pairs
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
DE69535243T2 (de) 1994-07-13 2007-05-10 Chugai Seiyaku K.K. Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP2471813B1 (en) 2004-07-15 2014-12-31 Xencor, Inc. Optimized Fc variants
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
EP1699826B1 (en) 2005-01-05 2009-03-11 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
KR101680906B1 (ko) 2007-09-26 2016-11-30 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
HRP20150279T1 (hr) 2007-12-26 2015-05-08 Xencor, Inc. Fc inaäśice s promijenjenim vezanjem na fcrn
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
JP5229888B2 (ja) * 2008-09-30 2013-07-03 独立行政法人産業技術総合研究所 弱酸性域での易解離性を向上したプロテインａ変異型タンパク質及び抗体捕捉剤
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
AU2011283694B2 (en) 2010-07-29 2017-04-13 Xencor, Inc. Antibodies with modified isoelectric points
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
WO2012132067A1 (ja) 2011-03-30 2012-10-04 中外製薬株式会社 抗原結合分子の血漿中滞留性と免疫原性を改変する方法
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
RU2014117505A (ru) 2011-09-30 2015-11-10 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула для ускорения удаления антигенов
EP2857419B1 (en) 2012-05-30 2021-01-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for eliminating aggregated antigens
WO2013180200A1 (ja) 2012-05-30 2013-12-05 中外製薬株式会社 標的組織特異的抗原結合分子
WO2014145159A2 (en) 2013-03-15 2014-09-18 Permeon Biologics, Inc. Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
JP6153801B2 (ja) 2013-07-23 2017-06-28 旭化成ホームズ株式会社 ノズル
JP2015185254A (ja) 2014-03-20 2015-10-22 日立マクセル株式会社 非水電解質二次電池

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007252368A (ja) * 2006-02-21 2007-10-04 Protenova Co Ltd イムノグロブリン親和性リガンド
EP1992692A1 (en) * 2006-02-21 2008-11-19 Protenova Co., Ltd. Immunoglobulin affinity ligand
EP2690173A1 (en) * 2011-03-25 2014-01-29 Kaneka Corporation Protein for affinity-separation matrix
US20160215027A1 (en) * 2013-09-04 2016-07-28 Protenova Co., Ltd. Multimeric immunoglobulin-binding domain
WO2016098357A1 (en) * 2014-12-19 2016-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
WO2017104783A1 (en) * 2015-12-18 2017-06-22 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use

Also Published As

Publication number Publication date
CA3136398A1 (en) 2020-10-15
BR112021020204A2 (pt) 2021-12-07
JPWO2020209318A1 (https=) 2020-10-15
US20220213140A1 (en) 2022-07-07
WO2020209318A1 (ja) 2020-10-15
MX2021012251A (es) 2021-11-12
TW202509054A (zh) 2025-03-01
EP3954696A1 (en) 2022-02-16
AU2020273072B2 (en) 2026-01-22
AU2020273072A1 (en) 2021-12-09
JP7583411B2 (ja) 2024-11-14
KR20210149779A (ko) 2021-12-09
EP3954696A4 (en) 2023-07-26
IL286982A (en) 2021-12-01
SG11202110986YA (en) 2021-11-29
TW202104244A (zh) 2021-02-01

Similar Documents

Publication Publication Date Title
JP7583411B2 (ja) Ｆｃ領域改変抗体の精製方法
KR102784832B1 (ko) Fc 영역 함유 폴리펩타이드의 정제를 효율화하기 위한 방법
US20210047387A1 (en) Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
US9284347B2 (en) Chromatographic method for purifying FC-containing proteins
CN110312734B (zh) 抗体分离能力改善的Fc结合性蛋白质及使用其的抗体的分离方法
JP2018184487A (ja) 抗体を精製する方法
CN107428817B (zh) 纯化白蛋白融合蛋白的方法
CN104640983A (zh) 亲和分离基质用蛋白质配体
CN107793477A (zh) 蛋白质纯化
US11945839B2 (en) Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
EP3615678A1 (en) Antibody selection method
JP2020531557A (ja) タンパク質の精製方法
CN106414495A (zh) 抗体处理方法
CA3214610A1 (en) Purification of antibodies by mixed mode chromatography
JP7788379B2 (ja) プロテインａアフィニティークロマトグラフィーを用いた生理活性ペプチドの精製方法
HK40061321A (en) Method for purifying fc region-modified antibody
Deol et al. Current advances in separation chemistry for antibody purification and analysis
Shukla et al. Downstream processing of Fc fusion proteins, bispecific antibodies, and antibody–drug conjugates
WO2024027120A1 (en) Multi-specific polypeptide complexes
WO2023175064A1 (en) Methods for purifying bispecific antibodies
HK40112179A (zh) 单域抗原结合性分子的纯化方法
Ghose et al. Considerations for Process Development
JP2020504172A (ja) 免疫グロブリン結合ポリペプチドおよびオリゴペプチドの免疫グロブリン結合容量を増加するための組成物および方法
HK1160474A (en) Methods for purification of single domain antigen binding molecules

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40061321

Country of ref document: HK